Published in J Infect on August 01, 2003
Coxiella burnetii and milk pasteurization: an early application of the precautionary principle? Epidemiol Infect (2006) 1.02
From Q Fever to Coxiella burnetii Infection: a Paradigm Change. Clin Microbiol Rev (2017) 0.93
Epidemiological study of Q fever in humans, ruminant animals, and ticks in Cyprus using a geographical information system. Eur J Clin Microbiol Infect Dis (2006) 0.90
Clinical spectrum of fever of intermediate duration in the south of Spain. Eur J Clin Microbiol Infect Dis (2008) 0.88
Molecular method for the characterization of Coxiella burnetii from clinical and environmental samples: variability of genotypes in Spain. BMC Microbiol (2012) 0.86
Clinical characteristics of Q fever and etiology of community-acquired pneumonia in a tropical region of southern Taiwan: a prospective observational study. PLoS One (2014) 0.83
Characteristics of hospitalized acute Q fever patients during a large epidemic, The Netherlands. PLoS One (2014) 0.80
A case of acute q Fever with severe acute cholestatic hepatitis. Gut Liver (2009) 0.79
Acute hepatitis associated with Q fever in a man in Greece: a case report. J Med Case Rep (2007) 0.77
Acute Q fever in febrile patients in northwestern of Iran. PLoS Negl Trop Dis (2017) 0.75
Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis (2011) 3.43
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS (2002) 2.28
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med (2003) 2.20
Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev (2012) 2.02
Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol (2009) 2.02
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin (2007) 1.83
The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics (2009) 1.83
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet (2002) 1.75
Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain ATCC 19606T with human lung epithelial cells, Galleria mellonella caterpillars, and mice. Infect Immun (2012) 1.57
Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation (2011) 1.53
Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl (2012) 1.53
Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl (2008) 1.48
Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol (2004) 1.46
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.43
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin (2004) 1.42
[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)]. Enferm Infecc Microbiol Clin (2004) 1.41
The changing etiology of fever of intermediate duration. Enferm Infecc Microbiol Clin (2010) 1.40
Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation. Liver Transpl (2011) 1.40
The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis (2007) 1.39
[Fever of intermediate duration]. Enferm Infecc Microbiol Clin (2003) 1.39
Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS One (2006) 1.32
Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res (2009) 1.30
Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother (2004) 1.27
Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses (2006) 1.26
Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun (2010) 1.24
West Nile virus past infections in the general population of Southern Spain. Enferm Infecc Microbiol Clin (2007) 1.23
Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore) (2003) 1.20
Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res (2008) 1.17
Presence of Rickettsia felis in the cat flea from southwestern Europe. Emerg Infect Dis (2002) 1.17
Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine (2011) 1.17
Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother (2013) 1.15
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother (2008) 1.14
Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol (2013) 1.13
Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis (2011) 1.13
Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase. Antimicrob Agents Chemother (2005) 1.13
Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother (2012) 1.10
Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS (2012) 1.09
Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother (2008) 1.08
Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother (2006) 1.07
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother (2008) 1.05
Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS (2010) 1.04
Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother (2006) 1.03
Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine (2010) 1.02
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther (2004) 1.01
Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort. J Womens Health (Larchmt) (2007) 1.01
Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect (2011) 1.00
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS (2004) 1.00
[Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people]. Enferm Infecc Microbiol Clin (2009) 0.98
Three-year multicenter surveillance of community-acquired Listeria monocytogenes meningitis in adults. BMC Infect Dis (2010) 0.97
Genetic variability among ampC genes from acinetobacter genomic species 3. Antimicrob Agents Chemother (2008) 0.97
Acinetobacter baumannii-induced lung cell death: role of inflammation, oxidative stress and cytosolic calcium. Microb Pathog (2011) 0.97
Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect (2003) 0.96
Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol (2012) 0.95
Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. Int J Antimicrob Agents (2011) 0.95
[Infectious complications in 159 consecutive kidney transplant recipients]. Enferm Infecc Microbiol Clin (2009) 0.95
Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia. J Acquir Immune Defic Syndr (2011) 0.92
[Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates]. Enferm Infecc Microbiol Clin (2006) 0.92
Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation (2013) 0.91
Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. Antivir Ther (2012) 0.91
Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences. AIDS Patient Care STDS (2005) 0.90
[In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010]. Enferm Infecc Microbiol Clin (2012) 0.90
Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int J Antimicrob Agents (2011) 0.90
Comparison of a repetitive extragenic palindromic sequence-based PCR method and clinical and microbiological methods for determining strain sources in cases of nosocomial Acinetobacter baumannii bacteremia. J Clin Microbiol (2002) 0.90
Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 0.90
Platelet-activating factor receptor initiates contact of Acinetobacter baumannii expressing phosphorylcholine with host cells. J Biol Chem (2012) 0.89
HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection. Curr HIV Res (2011) 0.89
Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrob Agents Chemother (2014) 0.89
Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis (2010) 0.88
GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin (2011) 0.88
Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Baltimore) (2011) 0.87
Role of fibronectin in the adhesion of Acinetobacter baumannii to host cells. PLoS One (2012) 0.87
Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest (2011) 0.87
What drives the number of high-risk human papillomavirus types in the anal canal in HIV-positive men who have sex with men? J Infect Dis (2013) 0.87
Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii. J Infect Dis (2013) 0.86
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med (2009) 0.86
Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr HIV Res (2009) 0.86
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. J Antimicrob Chemother (2008) 0.86
New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother (2009) 0.86
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy. AIDS (2014) 0.86
Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit (2007) 0.85
Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort). AIDS (2002) 0.85
Expression, purification, and refolding of biologically active Acinetobacter baumannii OmpA from Escherichia coli inclusion bodies. Protein Expr Purif (2010) 0.85
Acute toxicity of manganese in goldfish Carassius auratus is associated with oxidative stress and organ specific antioxidant responses. Ecotoxicol Environ Saf (2011) 0.84
Quantitative real-time PCR for detection of Acinetobacter baumannii colonization in the hospital environment. J Clin Microbiol (2012) 0.84
Molecular screening of Bartonella species in rodents from south western Spain. Vector Borne Zoonotic Dis (2008) 0.84
Anal squamous intraepithelial lesions are frequent among young HIV-infected men who have sex with men followed up at the Spanish AIDS Research Network Cohort (CoRIS-HPV). Int J Cancer (2013) 0.84
Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii. Antimicrob Agents Chemother (2013) 0.84
Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS (2016) 0.83
Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in HIV-infected patients. J Acquir Immune Defic Syndr (2013) 0.83
Positive predictive value of Leeds acinetobacter medium for environmental surveillance of Acinetobacter baumannii. J Clin Microbiol (2011) 0.83
Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort. J Clin Microbiol (2013) 0.83
Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (2012) 0.83
Clinical features of infections and colonization by Acinetobacter genospecies 3. J Clin Microbiol (2010) 0.83
[Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy]. Enferm Infecc Microbiol Clin (2003) 0.83
In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii. Antimicrob Agents Chemother (2009) 0.83